These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 16734362)

  • 1. [Problems of screening of novel antituberculosis antibiotics. 1. Present notions of specific biological properties of human tuberculosis pathogen Mycobacterium tuberculosis].
    Bibikova MV; Borisova NA; Orekhov SN; Katlinskiĭ AV
    Antibiot Khimioter; 2006; 51(1):22-7. PubMed ID: 16734362
    [No Abstract]   [Full Text] [Related]  

  • 2. [Problems of screening novel antituberculosis antibiotics. 3. New data on mechanism of action of antituberculosis agents].
    Bibikova MV; Borisova NA; Orekhov SN; Katlinskiĭ AV
    Antibiot Khimioter; 2006; 51(7):34-40. PubMed ID: 18035732
    [No Abstract]   [Full Text] [Related]  

  • 3. Hollow Fiber System Model for Tuberculosis: The European Medicines Agency Experience.
    Cavaleri M; Manolis E
    Clin Infect Dis; 2015 Aug; 61 Suppl 1():S1-4. PubMed ID: 26224766
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tuberculosis drug resistance: summary report for 2003.
    Can Commun Dis Rep; 2004 May; 30(10):93-5. PubMed ID: 15174496
    [No Abstract]   [Full Text] [Related]  

  • 5. Antituberculosis drug resistance: a global threat.
    Mohan A; Seth S
    Natl Med J India; 1998; 11(6):276-7. PubMed ID: 10083795
    [No Abstract]   [Full Text] [Related]  

  • 6. Mycobacterium tuberculosis evolutionary pathogenesis and its putative impact on drug development.
    Le Chevalier F; Cascioferro A; Majlessi L; Herrmann JL; Brosch R
    Future Microbiol; 2014; 9(8):969-85. PubMed ID: 25302954
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preclinical Efficacy Testing of New Drug Candidates.
    Nuermberger EL
    Microbiol Spectr; 2017 Jun; 5(3):. PubMed ID: 28643624
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tuberculosis: integrating host and pathogen biology. A summary of the 2005 Keystone Symposia.
    Fallows D; Murray RA; Kaplan G; Shinnick T
    Tuberculosis (Edinb); 2006 Mar; 86(2):144-8. PubMed ID: 16557661
    [No Abstract]   [Full Text] [Related]  

  • 9. Varying effects of common tuberculosis drugs on enhancing clofazimine activity in vitro.
    Zhang S; Shi W; Feng J; Zhang W; Zhang Y
    Emerg Microbes Infect; 2017 Apr; 6(4):e28. PubMed ID: 28442751
    [No Abstract]   [Full Text] [Related]  

  • 10. An in vitro antituberculosis drug sensitivity of isolates of Mycobacterium tuberculosis from human cases of pulmonary tuberculosis.
    Shah VM; Jhala CI
    J Indian Med Assoc; 1976 Aug; 67(3):57-9. PubMed ID: 828192
    [No Abstract]   [Full Text] [Related]  

  • 11. Drug resistance in tuberculosis.
    Ebrahim GJ
    J Trop Pediatr; 2007 Jun; 53(3):147-9. PubMed ID: 17526511
    [No Abstract]   [Full Text] [Related]  

  • 12. Evaluation of new antituberculosis drugs in mouse models.
    Davies GR; Pym AS; Mitchison DA; Nuermberger EL; Grosset JH
    Antimicrob Agents Chemother; 2007 Jan; 51(1):403; author reply 403-4. PubMed ID: 17182861
    [No Abstract]   [Full Text] [Related]  

  • 13. Drug resistance and fitness in Mycobacterium tuberculosis infection.
    Bottger EC; Pletschette M; Andersson D
    J Infect Dis; 2005 Mar; 191(5):823-4; author reply 824. PubMed ID: 15688309
    [No Abstract]   [Full Text] [Related]  

  • 14. Biphasic kill curve of isoniazid reveals the presence of drug-tolerant, not drug-resistant, Mycobacterium tuberculosis in the guinea pig.
    Ahmad Z; Klinkenberg LG; Pinn ML; Fraig MM; Peloquin CA; Bishai WR; Nuermberger EL; Grosset JH; Karakousis PC
    J Infect Dis; 2009 Oct; 200(7):1136-43. PubMed ID: 19686043
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Virulence and toxic properties of Mycobacterium tuberculosis sensitive and resistant to antitubercular preparations].
    Ginzburg TS; Klimenko MT
    Probl Tuberk; 1983 Jan; (1):63-7. PubMed ID: 6403937
    [No Abstract]   [Full Text] [Related]  

  • 16. [New antitubercular drugs].
    Krasucka-Kluźniak A
    Pneumonol Pol; 1990; 58(4-5):163-6. PubMed ID: 2168041
    [No Abstract]   [Full Text] [Related]  

  • 17. Anti-tuberculosis activity of some N-pentopyranosylamines.
    Moczulska A
    Acta Pol Pharm; 2004; 61(4):259-62. PubMed ID: 15575591
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Dynamics of the frequency of drug resistance in Mycobacterium tuberculosis].
    Volkova VD; Gunner AP; Erbosynov EE; Kadyrkhanova UT; Krivtsova AE
    Probl Tuberk; 1983 Mar; (3):54-8. PubMed ID: 6407001
    [No Abstract]   [Full Text] [Related]  

  • 19. [A comparative study of the susceptibilities to antituberculosis agents between Mycobacterium tuberculosis and Mycobacterium avium complex strains].
    Tsukamura M
    Kekkaku; 1987 Jun; 62(6):345-8. PubMed ID: 3116312
    [No Abstract]   [Full Text] [Related]  

  • 20. Antituberculosis activity of the molecular libraries screening center network library.
    Maddry JA; Ananthan S; Goldman RC; Hobrath JV; Kwong CD; Maddox C; Rasmussen L; Reynolds RC; Secrist JA; Sosa MI; White EL; Zhang W
    Tuberculosis (Edinb); 2009 Sep; 89(5):354-63. PubMed ID: 19783214
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.